Factsheet describing the long-term follow-up of the ASPEN trial -zanubrutinib vs ibrutinib in Waldenström’s macroglobulinemia (WM) patients.

ASPEN is an open-label, randomized, Phase 3 study comparing the safety, efficacy and clinical benefit of zanubrutinib

BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to fight cancer. Get up-to-date with the BeiGene hematology pipeline and clinical trials.

A summary of the latest developments from 12 studies in BTK inhibition in B-cell malignancies presented at EHA2022.

Poster presented at EHA2022 describing the results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia (WM).